Cullinan Therapeutics Inc
CGEMHealthcare|Biotechnology|USA
$18.13
-0.24 (-1.31%)
Tangible Book
$5.96
Earnings Power
$7.63
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04036682 A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | P1P2 | Active | 284 | Open-label | CLN-081 |
| NCT05879744 A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | NHL, NHL, Relapsed, Adult | P1 | Active | 90 | Open-label | CLN-978 |
| NCT05117476 A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | Advanced Solid Tumor, NSCLC | P1 | Active | 440 | Open-label | CLN-619, Pembrolizumab, Paclitaxel, Carboplatin AUC 6, pemetrexed, Datopotamab deruxtecan-dlnk (Dato-DXd) |
| NCT06381141 A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | P1 | Active | 30 | Open-label | CLN-619 |
| NCT07041099 A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | Sjögren, Sjogren Disease | P1 | Recruiting | 36 | Open-label | CLN-978 |
| NCT06613360 A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | SLE, SLE (Systemic Lupus) | P1 | Recruiting | 24 | Open-label | CLN-978 |
| NCT06994143 A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis (RA | P1 | Recruiting | 37 | Open-label | CLN-978 |
| NCT05143996 CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | P1 | Recruiting | 60 | Open-label | CLN-049 |
| NCT03682055 Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | P1P2 | Terminated | 14 | Open-label | VK-2019 |
| NCT06035744 CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Terminated | 23 | Open-label | CLN-617, Pembrolizumab |